Avai BioAVAI -6.27%24 Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 2,766 Software companies, Avai Bio ranks worse than 36153.25% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Avai Bio's Revenue for the
three
months ended in Dec. 2025 was $0.00 Mil. Avai Bio's average Accounts Receivable for the
three
months ended in Dec. 2025 was $0.00 Mil.
Avai Bio (OTCPK:AVAI) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Avai Bio Receivables Turnover Related Terms
Avai Bio Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Avai Bio's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVAI vs IPM, RCT, LPSN: Receivables Turnover Comparison
For the Software - Application subindustry, Avai Bio's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avai Bio Receivables Turnover vs Software Industry
For the Software industry and Technology sector, Avai Bio's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Avai Bio's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avai Bio (AVAI) has a Receivables Turnover of 0.00 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Avai Bio and its competitors. According to the industry distribution chart, Avai Bio ranks #999999 out of 2766 companies in the Software industry.
Is Avai Bio's Receivables Turnover too high?
Avai Bio's current Receivables Turnover is 0.00. Based on the distribution chart, Avai Bio ranks #999999 out of 2766 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's Receivables Turnover compare to IPM and RCT?
According to the Software industry distribution chart, Avai Bio ranks #999999 out of 2766 companies for Receivables Turnover. This places Avai Bio in the lower half of its industry. The industry median Receivables Turnover is 5.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Software company?
The median Receivables Turnover among Software companies is 5.67, based on 2,766 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Avai Bio and its competitors. For the Software industry, the median Receivables Turnover is 5.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avai Bio's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Avai Bio (AVAI), the current Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score
Get the complete analysis for AVAI
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVAI has been successfully added to your 
